Diagnosing Dx

In this episode of Diagnosing Dx, David Filby is joined by Kavya Swaminathan, PhD, Co-Founder and CEO of Kascaid . An immunologist and proteomics scientist by training, Kavya has spent her career studying immune dysregulation and biomarker discovery. That experience led to Kascaid and a fundamental question: can we understand chronic immune disease better by measuring what is happening far more fr...

In this episode of Diagnosing Dx, David Filby is joined by Paul Kase, Chief Commercial Officer at Lumos Diagnostics . Paul brings 30 years of healthcare experience, including more than 20 years in rapid point-of-care diagnostics. His history with FebriDx stretches back to its earliest development, and he now leads commercialisation as Lumos enters a major new phase following its US CLIA waiver. Pa...

In this episode of Diagnosing Dx, David Filby is joined by Marty Keiser, Founder and CEO of IVBH . After beginning his career in asset management and capital markets, Marty moved into biotech eight years ago with a focus on blood-based molecular diagnostics and early disease detection. That outside perspective shaped how he built IVBH, borrowing ideas from industries beyond diagnostics to create a...

In this episode of Diagnosing Dx, David Filby is joined by Raymond Tarr, Founder of Sagacity Diagnostics. Raymond brings more than 25 years of experience across diagnostics, rare disease, commercialisation and patient finding, with previous roles spanning companies including Cepheid and AstraZeneca/Alexion. His experience in rare disease, both professionally and personally, ultimately led to the c...

In this episode of Diagnosing Dx, David Filby is joined by Robert Carlson, Founder and President of Life Science Dx Consulting. Robert brings 30 years of experience across diagnostics and life sciences, spanning scientific, commercial, corporate development and executive leadership roles. He explains why early-stage diagnostics companies should think about partnerships much earlier, not only as a...

In this episode of Diagnosing Dx, David Filby is joined by Octavian Florescu, CEO of In Diagnostics. An electrical engineer and microchip designer by training, Octavian has spent his career exploring how semiconductor technology can be applied to blood testing. After building and exiting his first diagnostics company, he took those lessons into In Diagnostics alongside his co-founder and wife, Ana...

In this episode of Diagnosing Dx, David Filby is joined by Nicole Bell, CEO of Galaxy Diagnostics. Nicole’s route into vector-borne disease diagnostics is deeply personal. After her husband was initially diagnosed with early-onset Alzheimer’s disease, she continued searching for answers and later discovered he had Lyme disease alongside Babesia and Bartonella infections. That experience led Nicole...

In this episode of Diagnosing Dx, David Filby is joined by Andrew Miller, a diagnostics founder, advisor and two-time exited CEO. A scientist by training, Andrew founded and led companies focused on rapid molecular diagnostics, taking Ionian Technologies through acquisition by Alere and later building NAT Diagnostics , which was acquired by Becton Dickinson in 2020. The technology developed at Ion...

In this episode of Diagnosing Dx, David Filby is joined by Travis Wold, Chief Executive Officer at Imagenomix . Travis brings experience across cancer diagnostics, genomics, liquid biopsy, and international commercialization. We explore how Imagenomix is using AI to help make genomic testing more accessible to cancer patients globally. With around 98% of cancer patients outside the US not receivin...

In this episode of Diagnosing Dx, David Filby is joined by Nedal Safwat, Senior Vice President of Medical Diagnostics at Canatu and President of Canatu Inc. With more than 20 years in diagnostics, Nedal has held leadership roles across Cepheid, QIAGEN, bioMérieux and Luminex. He now leads Canatu’s expansion into medical diagnostics, taking the company’s carbon nanotube technology into point-of-car...

In this episode of Diagnosing Dx, David Filby is joined by Dean Remy, Co-Founder and Chief Commercial Officer at Mativa Diagnostics . Dean brings 35 years of experience across diagnostics, biotechnology, and therapeutics. He explains why pregnancy testing has barely changed in 50 years and how the traditional positive-or-negative result can leave women without critical information during the earli...

In this episode of Diagnosing Dx, David Filby is joined by Thomas Briggs, Chief Growth Officer at RedDrop Dx. Thomas brings more than 25 years of diagnostics and healthcare growth experience, spanning pharma, big diagnostics, medtech, and startup environments. In this conversation, we explore one of the most overlooked parts of diagnostics: blood collection, and why the process still looks far too...

In this episode of Diagnosing Dx, David Filby is joined by Alec Ford, Chief Executive Officer at Karius . Alec brings decades of leadership experience across therapeutics, vaccines, and genomics. In this conversation, we explore how Karius is bringing genomics into infectious disease and why the company has focused so sharply on immunocompromised patients. The scale of the unmet need is staggering...

In this episode of Diagnosing Dx, David Filby is joined by Alexander Bagaev, Chief Product Officer at BostonGene. Alexander has spent more than a decade helping build BostonGene from an early-stage team into a global precision medicine company. In this conversation, we explore why oncology is moving beyond single biomarkers and how BostonGene has expanded from diagnostics into AI-powered treatment...

In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire . Talia is a neuroscientist by training who spent more than a decade in academia, including time at Oxford , UC L, and Columbia , before moving into the startup world to get closer to real patient impact. In this conversation, we explore why precision medicine has transformed fields like oncology but st...

In this episode of Diagnosing Dx, David Filby is joined by Bharat Tewarie, MD, MBA, CEO at Helio Genomics .   Bharat has led Helio Genomics since July 2025, bringing decades of global healthcare leadership across pharma, biotech, diagnostics, and digital health. In this conversation, we explore why liver cancer surveillance still relies too heavily on outdated imaging, why so many high-risk patien...

In this episode of Diagnosing Dx, I’m joined by Jonathan Romanowsky, co-founder of Inflammatix and Principal at Kadima Spark. Jonathan shares lessons from leading diagnostics launches at CareDx, CardioDX, Veracyte, and Inflammatix. We discuss commercialization, reimbursement, fundraising, and why startups need to think about market adoption much earlier than before. We also explore Inflammatix’s e...

In this episode of Diagnosing Dx, I’m joined by Svetlana Nikic, Founder of Precision Oncology Consulting. Svetlana shares her journey from Roche and Illumina into building her own consultancy focused on helping diagnostics companies navigate the realities of market access in Europe. We explore the gap between innovation and implementation, why strong science alone does not guarantee patient access...

In this episode of Diagnosing Dx, I’m joined by Sara Barrington, CEO at Verici Dx. Sara explains how Verici Dx is tackling one of the biggest unresolved problems in kidney transplant care: helping clinicians monitor patients more precisely after transplant without relying so heavily on biopsies and legacy testing. We explore why balancing rejection risk against unnecessary immunosuppression is so...

In this episode of Diagnosing Dx, I’m joined by Arnon Chait, PhD, MBA, Chief Innovation Officer at Cleveland Diagnostics. Arnon shares his journey from NASA physicist to diagnostics innovator, and explains how Cleveland Diagnostics tackled one of the biggest challenges in prostate cancer testing: turning a widely used but flawed marker like PSA into something more clinically useful. We explore the...

In this episode of Diagnosing Dx, I’m joined by Serge Saxonov, Co-founder and CEO of 10x Genomics, a leader in single cell and spatial biology. Serge shares the story behind 10x Genomics, the evolution of its foundational technologies, and the launch of Atera, a new platform designed to enable whole transcriptome analysis in tissue at scale with single cell level sensitivity. We explore why biolog...

In this episode of Diagnosing Dx, I’m joined by Nathalya Mamane, Co-Founder and CEO at Anywhere Dx. Nathalya shares the origin story behind Anywhere Dx and how a personal pain point led her to build a diagnostics company focused on bringing molecular testing into the home. We explore why the current standard of care for infectious disease testing is still too slow, too expensive, and too dependent...

In this episode of Diagnosing Dx, I’m joined by MJ Hymes, Managing Partner at i5 BioPartners. MJ shares his journey from molecular biology into the commercial side of life sciences, and explains why great science alone is rarely enough to build a successful diagnostics or biotech company. We explore the gap between innovation and execution, why so many early-stage companies struggle to turn promis...

In this episode of Diagnosing Dx, I’m joined by Ajit Singh, CEO at Harbinger Health. Ajit has spent decades building, scaling, and investing in diagnostics companies, and this conversation draws on that full perspective. We explore why cancer diagnosis remains one of the biggest unresolved problems in care, what happens after suspicion enters the system, and why so many patients still face delays,...

This week I’m joined by Yana Aznavour, MD, PhD, OB-GYN surgeon and Founder & CEO of Endometrics. We unpack one of the biggest failures in modern healthcare: why women are still waiting up to 11 years for an endometriosis diagnosis, why the current standard still relies on surgery, and what it takes to build a diagnostic that clinicians will actually trust and use. This conversation goes beyond...